ZCZhichao Cheng

Zhichao Cheng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Zhichao Cheng has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Chuanhao Zhang

    Graduate School of Dalian Medical University, Dalian 116044, P. R. China; Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, P. R. China; The Key Laboratory of Biomarker High Throughput Screening and Target Translation of Breast and Gastrointestinal Tumor, Dalian University, Dalian 116001, P. R. China

    2 shared publications
  • Genghao Zhao

    Department of Medical Oncology Affiliated Zhongshan Hospital of Dalian University Dalian People's Republic of China

    2 shared publications
  • Ruoyu Wang

    Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

    2 shared publications
  • Zhe Wang

    Department of Medical Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, China

    2 shared publications
  • Bowen Hou

    Department of Medical Oncology Affiliated Zhongshan Hospital of Dalian University Dalian People's Republic of China

    1 shared publication
  • Shanshan Liang

    Affiliated Zhongshan Hospital of Dalian University Dalian China

    1 shared publication

Latest Publications

  • Age‐Related Risk Stratification in HPV ‐Positive Oropharyngeal Cancer: Implications for Treatment De‐Intensification

    by Chuanhao Zhang, Zhichao Cheng, Xin Jiang, Genghao Zhao, Yanmei Zhu, Bowen Hou, Yingming Sun, Shanshan Liang, Ye Zhang, Zhe Wang, et al.

    Background: Although the AJCC eighth edition staging system incorporates HPV status, it remains insufficient to guide personalized treatment in HPV‐positive oropharyngeal cancer (OPC). This study aimed to identify the optimal age threshold and evaluate its association with overall survival (OS) to improve risk stratification and inform individualized treatment strategies. Methods: Data were extracted from the SEER database (2018–2021), the University Health Network (UHN), University of Toronto, and the National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences (NCC). Only HPV‐positive OPC cases with complete survival records were included. The optimal age threshold was identified using restricted cubic spline modeling in combination with a recursive partitioning approach. Prognostic factors beyond HPV status and AJCC eighth edition stage were evaluated using multivariable Cox proportional hazards models. Recursive partitioning analysis (RPA) was used to construct a risk stratification model. The primary endpoint was OS. Results: Of the 10 283 eligible patients (87.9% male; median age, 62 years), 2.7% had distant metastases at diagnosis. Restricted cubic spline analysis revealed that 62 years of age represents an important critical threshold. Multivariable Cox analysis revealed that patients younger than 62 years exhibited significantly improved OS (HR, 0.61; 95% CI, 0.54–0.70; p < 0.001). RPA stratified patients into five risk groups with distinct 2‐year OS: extremely low (96.8%), low (93.7%), intermediate (86.1%), high (74.6%), and extremely high risk (47.5%). Among patients classified in the extremely low‐risk group (T0‐2N0‐1M0 and younger than 62 years), no significant difference in OS was observed between those treated with radiotherapy alone and those treated with chemoradiotherapy. External validation in the UHN ( N = 843) and NCC ( N = 167) cohorts suggested that extremely low‐risk patients might be spared concurrent chemotherapy. Conclusions: This study developed a risk stratification model for patients with p16‐positive OPC based on the AJCC eighth edition staging and age. Patients in the extremely low‐risk group may derive limited benefit from concurrent chemotherapy, suggesting that its omission could be considered in selected patients and may help guide the design of future de‐escalation trials.

  • Open Access

    APOBEC3B and CD274 as Combined Biomarkers for Predicting Response to Immunotherapy in Urothelial Carcinoma of the Bladder

    by Chuanhao Zhang, Zhichao Cheng, Zhe Wang, Genghao Zhao, Yonghui Yuan, Ruoyu Wang

    Immunotherapy has become a promising form of treatment for cancers. There is a need to predict response to immunotherapy accurately. In the UCSC Xena, pan-cancer analysis revealed a positive relationship between APOBEC3B (A3B) and tumor mutational burden ( , ) and microsatellite instability ( , ). Naturally, the A3B high expression group had higher tumor mutational burden and microsatellite instability than the low expression group. The bladder cancer (BLCA) cohort in The Cancer Genome Atlas (TCGA) revealed tumor mutational signatures of A3B high and low expression groups. Compared to the low expression group, the high expression group had a higher number of SNPs and mutations. Subsequently, A3B was profiled for immune cell infiltration and immune checkpoints in bladder cancer. The results showed that A3B was positively correlated with most immune cells. Compared with the A3B low expression group, the A3B high expression group had higher expression of immune checkpoints. A3B was positively correlated with CD274 ( , ). This indicated that the high expression of A3B may have a better response to immunotherapy. Furthermore, data from the IMvigor210 immunotherapy clinical trial was used to confirm the findings of this study. The combined survival analysis of A3B and CD274 showed that the group of patients with high expression of CD274 and A3B was found to have a significantly higher survival rate than the rest of the patient group ( ). The results demonstrated that A3B has a significant role in immunotherapy. Moreover, the combined biomarkers of A3B and CD274 were more effective in predicting response to immunotherapy in bladder urothelial carcinoma. The findings of this study provide valuable insights for precision medicine.